Abstract
Does rasagiline, a monoamine oxide type B inhibitor, retard the progression of Parkinson disease (PD)? The challenge in this situation is to demonstrate a disease-modifying effect distinct from the drug's clear beneficial effect on motor symptoms. In this study, researchers used a novel delayed-start design in which patients were randomized to receive either rasagiline (1 mg or 2 mg) or placebo for the first 36 weeks, followed by rasagiline for all participants for another 36 weeks. …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
